Across the United States, keeping your dog protected from heartworm disease increasingly requires passing a mandatory annual visit and diagnostic test. No FDA-approved label requires it. The American Heartworm Society's own waiver form acknowledges owners can decline it. It originated not from a patient safety concern — but from a federal surveillance request made to a guideline body funded by the manufacturers who benefit from it.
The Issue
At most U.S. veterinary clinics today, a dog owner who wants to refill their pet's heartworm prevention medication — even after years of documented continuous use — must first pay for an annual antigen test and wellness visit before the prescription will be renewed. No exceptions. No waivers.
"The heartworm test is not a state-mandated legal requirement, but it is a strict veterinary requirement required to prescribe prevention. Technically, a doctor can [prescribe without it]."
— Tampa Bay area veterinary clinic staff member, March 2026This briefing does not argue against heartworm testing. It argues against mandating it as a non-negotiable precondition for renewing prevention prescriptions for established, compliant dogs — a policy shift that lacks adequate clinical justification, exceeds the scope of veterinary prescribing authority, and was shaped by a guideline-setting process with undisclosed financial conflicts of interest.
The American Heartworm Society, the primary source of this standard, is financially sponsored by the four largest manufacturers of ML preventive drugs and IDEXX Laboratories — the manufacturer of the diagnostic test the standard requires. Neither the AHS guidelines nor the FDA-approved drug labels disclose this relationship.
A direct review of all 8 major FDA-approved ML preventive labels confirms: not one requires pre-administration testing at prescription renewal. All testing language is limited to initiation. Advantage Multi contains no testing language at all.
AHS Research Chair Tom Nelson DVM confirmed in March 2026 that the annual testing recommendation was introduced at the FDA's request for post-market surveillance — not as a patient safety determination. The geographic limitation was silently removed when AHS translated it into a national standard.
The AHS publishes an official Heartworm Preventive Waiver template (© 2020 AHS) on its own website. A practice that refuses to accept a signed waiver is not following AHS guidance — it is going beyond it.
Manufacturer satisfaction guarantees (up to $1,500 coverage) explicitly condition eligibility on annual negative testing. Owners who sign a waiver are waiving a financial warranty — not bypassing a clinical safeguard. This distinction is not disclosed at the point of care.
The Evidence
The clinical argument alone is strong but dismissible as a technical dispute. The conflict-of-interest argument alone is suggestive but not conclusive. Together they describe a professional standard that has hardened beyond what evidence supports — in a direction that consistently benefits its commercial sponsors.
The safety rationale fails at renewal for consistently-dosed, asymptomatic patients.
Veterinary prescribing authority was delegated to protect the individual patient — not to enforce population surveillance or manufacturer warranty terms.
The guideline origin is surveillance, not patient safety — set by a body financially dependent on the outcome it recommends.
The Numbers
Calculate what annual heartworm prevention costs for your dog — and what the mandatory visit requirement adds on top of it.
Select your dog's size, preferred medication, and local pricing. See what the mandate adds above the cost of protection alone.
Range $65–$150; national average per AVMA 2025. Actual price varies by region and practice type.
Cited range $35–$75 (Sulik K. DVM, PetMD 2025). Default: confirmed real-world price including draw and materials.
If an owner skips prevention due to this cost barrier and their dog contracts heartworm, treatment costs $600–$3,000+ — melarsomine injections, doxycycline, chest X-rays, 6–8 weeks crate rest. Severe caval syndrome cases: $3,000–$6,000.
Source: Sulik K. DVM, reviewed by Coates J. DVM, PetMD April 2025
Take Action
You have more options than you may have been told. Here's what to know before your next vet visit.
The American Heartworm Society publishes an official Heartworm Preventive Waiver template that any practice can use. Ask your veterinarian if they will accept a signed waiver in lieu of testing. If they decline, ask them to explain the legal basis for that policy — not the clinical preference, the legal basis.
Download the AHS Waiver PDF →Major ML manufacturers (Boehringer Ingelheim, Elanco, Zoetis) offer satisfaction guarantees covering up to $1,500 in treatment costs if a dog on their product develops heartworm. These guarantees require annual negative testing. Ask your vet to explain this — it's rarely disclosed at the point of care.
See Section 3.7 of the White Paper →The 40-page white paper documents the clinical, legal, and structural case in full, with primary source citations. Many veterinarians are implementing practice policy, not exercising independent clinical judgment. Sharing the evidence gives them the opportunity to reconsider.
Download the White Paper →This initiative is building a coalition of dog owners, veterinary professionals, consumer advocates, and policy researchers who believe prevention should be accessible without unnecessary gatekeeping. If you've encountered this issue, we want to hear from you — and we'll keep you informed as this work develops.
Your information is used only to follow up on this issue. It is never sold or shared.
No spam. Updates only when there is something meaningful to share.
Press & Resources
The full white paper documents every claim with primary source citations. Press inquiries welcome.
The Annual Heartworm Testing Mandate: Clinical Evidence, Guideline Integrity, and Owner Autonomy
Three integrated lines of argument — clinical, autonomy-based, and structural — supported by FDA DailyMed label analysis, direct primary source correspondence with AHS Research Chair Tom Nelson DVM, AHS guideline review, manufacturer guarantee documentation, and CAPC prevalence data.
↓ Download White Paper (PDF)